Vanguard Group’s Unicycive Therapeutics UNCY Stock Holding History

Vanguard Group’s Portfolio UNCY Stock Details UNCY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$4.55M	Buy	788,587 +129,709	+20%	+$692K	﹤0.01%	3290
2025 Q3	$2.87M	Buy	658,878 +52,925	+9%	+$231K	﹤0.01%	3461
2025 Q2	$2.89M	Buy	605,953 +484,709	+400%	+$3M	﹤0.01%	3400
2025 Q1	$697K	Buy	121,244 +7,422	+7%	+$45.3K	﹤0.01%	3810
2024 Q4	$904K	Hold	113,822	–	–	﹤0.01%	3794
2024 Q3	$464K	Hold	113,822	–	–	﹤0.01%	3989
2024 Q2	$570K	Buy	113,822 +79,836	+235%	+$785K	﹤0.01%	3957
2024 Q1	$469K	Buy	33,986 +22,480	+195%	+$273K	﹤0.01%	4029
2023 Q4	$99.8K	Hold	11,506	–	–	﹤0.01%	4301
2023 Q3	$98.9K	Hold	11,506	–	–	﹤0.01%	4352
2023 Q2	$147K	Hold	11,506	–	–	﹤0.01%	4353
2023 Q1	$242K	Buy	11,506 +9,236	+407%	+$92K	﹤0.01%	4294
2022 Q4	$12.3K	Hold	2,270	–	–	﹤0.01%	4505
2022 Q3	$13K	Hold	2,270	–	–	﹤0.01%	4597
2022 Q2	$19K	Hold	2,270	–	–	﹤0.01%	4614
2022 Q1	$29K	Hold	2,270	–	–	﹤0.01%	4623
2021 Q4	$47K	Buy	+2,270	New	+$56.8K	﹤0.01%	4628

Other funds holding UNCY

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Cantor Fitzgerald New York $9.23B AUM 74.49% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Vanguard Group's UNCY Position: Q4 2025 in Review

Vanguard Group increased its Unicycive Therapeutics (UNCY) stake by 20% in Q4 2025, buying an estimated $692K and bringing the position to 788,587 shares worth $4.55M. The position accounts for ﹤0.01% of the portfolio, ranked #3290.

Vanguard Group first reported a position in UNCY in Q4 2021 and has held it in 17 quarters since. 35 funds tracked by Wall St. Rank hold UNCY as of Q4 2025.

Vanguard Group held 788,587 shares of Unicycive Therapeutics worth $4.55M as of Q4 2025.
Vanguard Group bought 129,709 Unicycive Therapeutics shares in Q4 2025, an estimated $692K.
Unicycive Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3290 holding.
Vanguard Group first reported a position in Unicycive Therapeutics in Q4 2021 and has held it in 17 quarters since.
35 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.